CYPHERPUNK TECHNOLOGIES INC. Deferred Costs, Noncurrent
CYPHERPUNK TECHNOLOGIES INC. (CYPH) had Deferred Costs, Noncurrent of $348.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2026-08-12
- 2026-06-30: Deferred Costs, Noncurrent $348.00K.
- 2026-03-31: Deferred Costs, Noncurrent $385.00K.
- 2025-12-31: Deferred Costs, Noncurrent $401.00K.
- 2025-09-30: Deferred Costs, Noncurrent $80.00K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2026-06-30 | $348.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $385.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $401.00K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $80.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |